GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LumiraDx Ltd (OTCPK:LMDWF) » Definitions » Inventories, Finished Goods

LumiraDx (LumiraDx) Inventories, Finished Goods : $27.47 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is LumiraDx Inventories, Finished Goods?

LumiraDx's quarterly finished goods declined from Dec. 2022 ($68.42 Mil) to Mar. 2023 ($0.00 Mil) but then increased from Mar. 2023 ($0.00 Mil) to Jun. 2023 ($27.47 Mil).

LumiraDx's annual finished goods increased from Dec. 2020 ($50.05 Mil) to Dec. 2021 ($62.41 Mil) and increased from Dec. 2021 ($62.41 Mil) to Dec. 2022 ($68.42 Mil).


LumiraDx Inventories, Finished Goods Historical Data

The historical data trend for LumiraDx's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LumiraDx Inventories, Finished Goods Chart

LumiraDx Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Inventories, Finished Goods
- 50.05 62.41 68.42

LumiraDx Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 105.54 - 68.42 - 27.47

LumiraDx Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


LumiraDx (LumiraDx) Business Description

Traded in Other Exchanges
Address
C/o Ocorian Trust (Cayman) Ltd, Windward 3, P.O. Box 1350, Regatta Office Park, Grand Cayman, CYM, KY1-1108
LumiraDx Ltd is a next-generation point of care diagnostics company. It manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. Geographical presence in United States, Italy, UK, Germany, Colombia, Sweden and Other countries. Majority revenue derives from U.S.